Fragment-Screen From fragments to high affinity binders interfacing integrated structural biology, medicinal chemistry and artificial intelligence
- Coordinator
- Instruct-Eric, United Kingdom
- Runs
- 1 February 2023 to 31 January 2027
- Status
- Running
- EU funding
- €8.3m
- Total cost
- €8.3m
- Partners
- 26 organisations in 11 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101094131
What the project is doing
In the project's own words, from its summary on CORDIS.
Fragment-Screen will develop innovative instrumentation, workflows and experimental and computational methodologies for fragment-based drug discovery (FBDD) enabling access to early phase structure-based drug discovery for all biological targets and for scientists both in industry and academia. The established workflows will use structural biology insights and associated data to feed artificial intelligence (AI) methodology to guide medicinal chemistry in drug development.
Fragment-Screen brings together scientists from four ESFRI Landmark research infrastructures (RIs): ESRF (the European synchrotron) and the distributed RIs EU-OPENSCREEN ERIC (medicinal chemistry), ELIXIR (data resources for life science) under the coordination of Instruct-ERIC (integrated structural biology) and seven industry partners in scientific instrumentation and computational and AI sectors including SMEs to remove crucial bottlenecks in early phase drug discovery.
The new instrumentation and workflows will be available at European RIs, while the new instruments will be commercialised to increase the technological competitiveness of European industry in drug design and the attractiveness of structural biology RIs for the pharmaceutical and biotech sectors. Fragment-Screen will implement open science approaches in early drug discovery to maximise the impact of screening campaigns.
Generated data will be made accessible so that iterative cycles applying AI will improve response times for drug discovery. We will create a framework for the objective and independent evaluation of AI in drug design to identify critical developments in this thriving research field. Methodologies for rigorous cross-validation will be established through demonstrator and pilot studies and results will be disseminated to the large scientific communities affiliated to the European RIs and beyond.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Instruct-Eric | Oxford | United Kingdom | Coordinator |
| Ibm Research GmbH | Rueschlikon | Switzerland | Associatedpartner |
| Masarykova univerzita | Brno | Czechia | Participant |
| Bruker Biospin GmbH & Co Kg | Ettlingen | Germany | Participant |
| Bruker Biospin Holding Se | Ettlingen | Germany | Participant |
| European Infrastructure of Open Screening Platforms for Chemical Biology European Research Infrastucture Consortium (eu-Openscreen Eric) | Berlin | Germany | Participant |
| European Molecular Biology Laboratory | Heidelberg | Germany | Participant |
| Johann Wolfgang Goethe-Universitaet Frankfurt Am Main | Frankfurt Am Main | Germany | Participant |
| Signals GmbH & Co. Kg | Frankfurt Am Main | Germany | Participant |
| Danmarks Tekniske Universitet | Kongens Lyngby | Denmark | Participant |
| Agencia Estatal Consejo Superior De Investigaciones Cientificas | Madrid | Spain | Participant |
| Alpx | Grenoble | France | Participant |
| Arinax | Moirans | France | Participant |
| European Synchrotron Radiation Facility | Grenoble | France | Participant |
| Consorzio Interuniversitario Risonanze Magnetiche Di Metallo Proteine | Firenze | Italy | Participant |
| Valsts zinatniskais instituts ""Nacionalais petniecibas un inovaciju instituts"""" | Riga | Latvia | Participant |
| Fei Electron Optics BV | Eindhoven | Netherlands | Participant |
| Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis | Amsterdam | Netherlands | Participant |
| Universiteit Utrecht | Utrecht | Netherlands | Participant |
| Faculdade De Ciencias Da Universidade De Lisboa | Lisboa | Portugal | Third party |
| Fciencias.id - Associacao Para a Investigacao E Desenvolvimento De Ciencias | Lisbon | Portugal | Participant |
| Faculdade de Farmácia da Universidade de Lisboa | Lisboa | Portugal | Participant |
| Astex Therapeutics Limited | Cambridge | United Kingdom | Associatedpartner |
| Diamond Light Source Limited | Didcot | United Kingdom | Associatedpartner |
| United Kingdom Research and Innovation | Swindon | United Kingdom | Associatedpartner |
| University of Leeds | Leeds | United Kingdom | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI